📊 ALGS Key Takeaways
Is Aligos Therapeutics, Inc. (ALGS) a Good Investment?
Aligos Therapeutics exhibits development-stage biotech characteristics with minimal revenue ($2.8M), severe operating losses (-$26.9M), and annual cash burn of $23.3M, yielding approximately 15 months of financial runway at current rates. While YoY improvements in net income (+81.6%) and EPS (+88.3%) suggest operational progress, the company requires significant clinical/regulatory milestones or capital raises to survive.
Aligos Therapeutics shows very weak fundamentals: minimal revenue, extremely negative operating and net margins, and deeply negative free cash flow. While the latest net loss improved year over year and the balance sheet has no long-term debt, the cash balance appears small relative to the annual operating cash burn, making funding risk and dilution risk the central fundamental concerns.
Why Buy Aligos Therapeutics, Inc. Stock? ALGS Key Strengths
- YoY improvement in net loss indicates operational progress and cost management
- No debt burden with clean capital structure and zero leverage
- Current ratio of 2.56x demonstrates adequate short-term liquidity
- Debt-free capital structure reduces financial leverage risk
- Current ratio and quick ratio of 3.90x indicate near-term liabilities are manageable
- Year-over-year improvement in net income and EPS suggests reported losses narrowed
ALGS Stock Risks: Aligos Therapeutics, Inc. Investment Risks
- Limited financial runway of approximately 15 months at current burn rate
- Minimal revenue base of $2.8M against $26.9M operating losses
- Extreme negative margins (-951.6% operating, -814.1% net) indicate fundamental unprofitability
- Heavy reliance on capital markets or major clinical milestone achievement for survival
- Revenue base is too small to support the cost structure, with operating margin at -4024.9%
- Operating cash flow of -$82.50M versus cash of $18.30M implies limited cash runway without new financing
- Improvement in net income quality is questionable because core operations remain deeply unprofitable
Key Metrics to Watch
- Quarterly cash burn rate and cash position trends
- Revenue growth and clinical development milestone announcements
- Operating loss trajectory and path to profitability timeline
- Cash runway relative to quarterly operating cash burn
- Pipeline progress translating into collaboration revenue, milestone payments, or meaningful expense reduction
Aligos Therapeutics, Inc. (ALGS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.56x current ratio provides a solid financial cushion.
ALGS Profit Margin, ROE & Profitability Analysis
ALGS vs Healthcare Sector: How Aligos Therapeutics, Inc. Compares
How Aligos Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aligos Therapeutics, Inc. Stock Overvalued? ALGS Valuation Analysis 2026
Based on fundamental analysis, Aligos Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aligos Therapeutics, Inc. Balance Sheet: ALGS Debt, Cash & Liquidity
ALGS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aligos Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-20.94 indicates the company is currently unprofitable.
ALGS Revenue Growth, EPS Growth & YoY Performance
ALGS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $311.0K | -$23.0M | $-2.11 |
| Q3 2025 | $741.0K | -$4.3M | $-0.44 |
| Q2 2025 | $965.0K | $5.1M | $0.81 |
| Q1 2025 | $311.0K | -$34.9M | $-2.11 |
| Q3 2024 | $1.1M | -$18.0M | $-3.07 |
| Q2 2024 | $1.1M | $5.1M | $0.03 |
| Q1 2024 | $140.0K | -$23.0M | $-0.22 |
| Q3 2023 | N/A | -$18.0M | $-0.41 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aligos Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ALGS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aligos Therapeutics, Inc. (CIK: 0001799448)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALGS
What is the AI rating for ALGS?
Aligos Therapeutics, Inc. (ALGS) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 81% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALGS's key strengths?
Claude: YoY improvement in net loss indicates operational progress and cost management. No debt burden with clean capital structure and zero leverage. ChatGPT: Debt-free capital structure reduces financial leverage risk. Current ratio and quick ratio of 3.90x indicate near-term liabilities are manageable.
What are the risks of investing in ALGS?
Claude: Limited financial runway of approximately 15 months at current burn rate. Minimal revenue base of $2.8M against $26.9M operating losses. ChatGPT: Revenue base is too small to support the cost structure, with operating margin at -4024.9%. Operating cash flow of -$82.50M versus cash of $18.30M implies limited cash runway without new financing.
What is ALGS's revenue and growth?
Aligos Therapeutics, Inc. reported revenue of $2.8M.
Does ALGS pay dividends?
Aligos Therapeutics, Inc. does not currently pay dividends.
Where can I find ALGS SEC filings?
Official SEC filings for Aligos Therapeutics, Inc. (CIK: 0001799448) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALGS's EPS?
Aligos Therapeutics, Inc. has a diluted EPS of $-2.21.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ALGS a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Aligos Therapeutics, Inc. has a SELL rating with 81% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ALGS stock overvalued or undervalued?
Valuation metrics for ALGS: ROE of -72.5% (sector avg: 15%), net margin of -814.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ALGS stock in 2026?
Our dual AI analysis gives Aligos Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALGS's free cash flow?
Aligos Therapeutics, Inc.'s operating cash flow is $-23.1M, with capital expenditures of $130.0K. FCF margin is -821.8%.
How does ALGS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -814.1% (avg: 12%), ROE -72.5% (avg: 15%), current ratio 2.56 (avg: 2).